Biodistribution studies showed that injection into the lymph node delivered antigen more efficiently to subcutaneous lymph nodes than subcutaneous injection. Conclusions: As intralymphatic immunisation induced more than 10-fold higher IgG2a responses with 100-fold lower allergen doses than subcutaneous immunisation, this approach should allow to reduce both the number of allergen injections as well as the allergen dose, improving both efficacy and safety of SIT.
juvants used [6] [7] [8] , the dosage form [9] [10] [11] , as well as the route of allergen administration [12] [13] [14] .
Immune responses are induced in secondary lymphoid organs, where professional antigen-presenting cells present antigenic epitopes to lymphocytes, and where Tand B-cell interactions take place. If antigens stay outside organised lymphoid tissues, then even large amounts of antigens can be ignored by the immune system [15, 16] . Therefore, antigen localisation is an important regulator of the immune response. Accordingly, direct administration of antigens into lymph nodes should be a more efficient route of immunisation. We have already demonstrated this for the administration of naked DNA vaccines [17] , major histocompatibility complex class I binding peptide vaccines [18] and tumour cells [19] . In the present study, we compared subcutaneous with direct intralymphatic administration of allergens in mice as a means for improving the efficacy of SIT.
Methods

Immunisation Protocols
Female CBA mice (6-8 weeks old; Harlan, Horst, The Netherlands) were immunised 3 times with 2-week intervals by injection with the major bee venom allergen phospholipase A 2 (PLA 2 ; n = 5; Sigma-Aldrich, Buchs, Switzerland) or recombinant Fel d 1 (n = 4), the major cat allergen. Fel d 1 was cloned into the pQE30 expression vector (Qiagen, Hilden, Germany) as an N-terminal [His] 6 -tag fusion protein, produced in Escherichia coli and purified as described [20] . The lipopolysaccharide content of Fel d 1 was 1.27 ng/mg of protein, as determined by the Limulus amoebocyte lysate assay. Different doses of the allergens were mixed with aluminium hydroxide (Alhydrogel 3%; Brenntag Biosector, Fredrikssund, Denmark) and saline 1 h before intralymphatic injection into the inguinal lymph node [18] or subcutaneously at the base of the tail. The doses of aluminium hydroxide were 90 and 450 g, for intralymphatic and subcutaneous injections, respectively, and the injection volumes were 10 and 50 l. Serum was prepared from tail vein blood drawn at different time points and frozen at -20 ° C until analysed by ELISA.
Alternatively, the 2 routes of administration were tested in a therapeutic model in CBA mice that were first sensitised with cat fur allergen extract (Stallergènes, Fresnes, France) by 6-weekly intraperitoneal injections. The allergen extract (1 g/dose) was adsorbed to aluminium hydroxide (900 g/dose) and injected in a volume of 100 l. Two weeks after the last sensitisation injection, groups of 4 mice each were desensitised with 1 g Fel d 1 by intralymphatic or subcutaneous injections as described above. As positive control, a group of sensitised but not treated mice was used, while naïve mice were used as negative controls. For the induction of anaphylaxis, all 4 groups of mice were challenged, 3 weeks after the last desensitisation injection, with 30 g of cat fur allergen extract in saline (50 l i.p.), and the body temperature was measured with a calibrated digital thermometer before and 30 min after the challenge. All animal experiments were approved by and performed according to guidelines from the Swiss veterinary authorities.
Antibody Measurements
For antibody detection, 96-well microtitre plates (Nunc Maxisorb, Basel, Switzerland) were coated with 1 g/ml cat fur allergen extract (Stallergènes) or 5 g/ml of PLA 2 (Sigma) in carbonate buffer and incubated overnight at 4 ° C. After blocking the plates with 2.5% non-fat dry milk in PBS-0.05% Tween-20 (PBSTM), serial dilutions of individual sera in PBSTM were added to the plates and incubated for 2h. Then plates were incubated with 1 g/ml biotinylated goat anti-mouse IgG1 or IgG2a (BD Pharmingen, San Diego, Calif., USA) in PBSTM, followed by incubation with a 1: 1,000 dilution of streptavidin-conjugated horseradish peroxidase (BD Pharmingen). In the last step, plates were incubated with the enzyme substrate 2,2-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid) di-ammonium salt (Sigma-Aldrich) in 1 M sodium dihydrogen phosphate. The absorption was read at 405 nm on a Model 550 Microplate reader (Bio-Rad, Hercules, Calif., USA). Unless otherwise specified, all incubations were done at room temperature and were intercepted with PBST washes.
For detection of PLA 2 -specific IgE antibodies, plates were coated with 2 g/ml of anti-mouse IgE capture antibody (BD Pharmingen). As secondary reagent for binding to mouse serum, an in-house biotinylated PLA 2 was used at 3 g/ml.
For detection of Fel d 1-specific IgE antibodies, plates were coated with anti-mouse IgE (BD Pharmingen) at 2 g/ml and then incubated for 2 h with serum samples from immunised mice. Subsequently, rFel d 1 was added at 0.6 M and the plates incubated for another 90 min. For detection, anti-Fel d 1-biotin antibody (Indoor Biotechnology, Warminster, UK) at 1: 1,000 dilution (90 min) was used.
Flow Cytometry and Cytokine Secretion Assay
One week after the last injection of allergen, spleens were isolated and single-cell suspensions were prepared. For intracellular staining of interferon (IFN)-␥ , red blood cell-free splenocytes 1 ! 10 6 were stimulated overnight with 0.5 g/ml ionomycin and 5 g/ml heat-denatured PLA 2 , the last 4 h in the presence of brefeldin A. After blocking of Fc receptors (anti-CD16/CD32), the splenocytes were fixed in PBS/PFA 1% for 10 min and permeabilised in PBS/NP40 0.1% for 3 min. Thereafter, the cells were stained with FITC-labelled antibodies specific for CD8 or CD4, as well as PE-labelled anti-CD44 and antigen-presenting cell-labelled anti-IFN-␥ for 30 min at 4 ° C. All antibodies were purchased from BD Pharmingen.
For analysis of cytokine secretion by ELISA, triplicates of 8 ! 10 5 cells were cultured with 10 g/ml LoTox Fel d 1 from Indoor Biotechnology or left unstimulated in 200 l of IMDM supplemented with 5% FCS, sodium pyruvate, L -glutamine, penicillin and streptomycin. The cytokines secreted in the supernatant were measured using the DuoSet ELISA from R&D Systems (Abingdon, UK) after 20 h (IL-2) or after 72 h (IL-4, IL-10 and IFN-␥ ). The detection limit for IFN-␥ and IL-10 was 30 pg/ml and for IL-2 and IL-4 15 pg/ml.
Biodistribution
To compare the relative biodistribution of intralymphatically and subcutaneously administered proteins, CBA mice were injected with 99m Tc pertechnetate-labelled human immunoglobu-lin (TechneScan HIG) from Mallinckrodt Medical B.V., Petten, The Netherlands; the half life of 99m Tc is approximately 6 h. The radioactive protein was injected intralymphatically in the inguinal lymph node or subcutaneously in the inguinal region at 3 MBq per dose. Four animals each were euthanised 90 min and 17 h after injection. Lungs, spleen, liver and inguinal lymph nodes were dissected and analysed directly in a Cobra II gamma counter (Packard Bioscience, Dreieich, Germany). The absolute distribution to each organ was expressed as radioactive count per minutes.
Statistics
Differences between independent groups were tested by nonparametric statistical analysis. Data were presented as means 8 standard error and compared using a 2-sided independent MannWhitney U test or Kruskal-Wallis one-way analysis of variance with Dunn's multiple comparison test. The significance level was set at 5%.
Results
Intralymphatic Immunisation with Bee Venom PLA 2 Enhanced Immune Responses
To asses the influence of the route of administration on the immunogenicity of allergens, mice were immunised thrice with 2-week intervals using either 0.1 or 10 g of the bee venom major allergen PLA 2 either by subcutaneous or intralymphatic injections. As illustrated in figure 1 a, a dose as small as 0.1 g PLA 2 was sufficient to induce high PLA 2 -specific IgG2a titers by intralymphatic injection. In order to induce comparable titers by subcuntaneous injections, 10 g of PLA 2 were necessary. Similar differences were observed for IgG1. Neither intralymphatic nor subcutaneous injections induced significant IgE titres.
In a similar experiment, 7 days after the last immunisation with 1 g PLA 2 , splenocytes were re-stimulated in vitro for analysis of IFN-␥ secretion by flow cytometry. As illustrated in figure 1 b, intralymphatic injections elicited significantly higher CD8 T-cell responses than subcutaneous injections.
Intralymphatic Immunisation Also Enhanced Immune Responses to Cat Fur Allergen Fel d 1
The following experiments aimed at expanding the above observations to another allergen. The perennial major cat fur allergen Fel d 1 was intralymphatically injected into mice at doses of 0.1 and 1 g and compared with the subcutaneous injection of 10 g Fel d 1. Comparably high IgG1 levels were induced in all 3 groups of mice, independent of the route of administration or the . 3 ) . The cytokine secretion was typically higher in cultured cells from mice that had been immunised by intralymphatic allergen administration, and the differences between stimulated and non-stimulated cells only reached statistical significance in the intralymphatically injected group.
Immunotherapy by Intralymphatic Fel d 1 Administration Enhanced Protection against Anaphylaxis
Mice were sensitised using repeated low-dose intraperitoneal injections of cat fur allergen extract, inducing significant levels of allergen-specific serum IgE and IgG1, but no detectable IgG2a (data not shown). These allergic mice were subsequently desensitised with Fel d 1, by 3 intralymphatic or subcutaneous injections with 2-week intervals. Again, a stronger IgG2a response was observed after intralymphatic allergen administration than after the subcutaneous injections ( fig. 4 a) . Three weeks after completion of immunotherapy, mice were intraperitoneally challenged with a high dose of cat fur allergen extract and subsequently monitored for anaphylaxis, which in mice manifests as a drop in body temperature. As illustrated in figure 4 b, immunotherapy by intralymphatic administration of Fel d 1 induced significant protection against anaphylactic temperature drop (p = 0.048). In contrast, subcutaneous immunotherapy was not sufficient to protect sensitised mice against the temperature drop.
Intralymphatic Injections Caused Accumulation of Allergen in Lymphoid Tissue
One possible explanation to the observed benefit of intralymphatic over subcutaneous immunotherapy could be an inefficient drainage to secondary lymphatic tissue after subcutaneous injections, i.e. intralymphatic injections deliver more antigen to the site of immune response induction. This difference in allergen dose available for stimulation of allergen-specific lymphocytes may also lead to an increase in the Th1 immune responses observed after intralymphatic allergen administration. Hence, to analyse the fate of an injected protein as a function of the administration route, mice received either intralymphatic or subcutaneous injections of a human immunoglobulin labelled with radioactive technetium. As illustrated in figure 5 , analysis of the radioactivity in different organs 90 min after injection revealed that more radioactivity was measured in inguinal lymph nodes after intralymphatic administration than after subcutaneous injection (p ! 0.05). In contrast, subcutaneously administered protein drained more rapidly to the liver (p ! 0.05). Seventeen hours after injection, radioactivity was generally reduced in all organs, but again, approximately 10 times more radioactivity could be detected in the inguinal lymph nodes of mice injected by the intralymphatic route than by the subcutaneous route (p ! 0.05).
Discussion
IgE-mediated allergies, such as allergic rhinoconjunctivitis and asthma, have become highly prevalent, affecting up to 35% of the population in industrialised countries [21] [22] [23] . The best long-lasting treatment available for these patients is SIT [24] . However, the major problems of current SIT regimes are the long-term commitment of the patient, the high treatment costs, and the significant risk of allergic adverse reactions associated with the allergen administration [2] . One approach for improving SIT focuses on the route of allergen administration. In this respect, sublingual immunotherapy, in which the allergen is given as soluble tablets or drops, and local nasal immunotherapy have proven promising and especially attractive for patients [1, [25] [26] [27] . However, the treatment duration of sublingual immunotherapy and nasal SIT remains similar to that of current subcutaneous SIT [28] , and the required allergen doses are at least 50-100 times After 90 min and after 17 h, the mice were euthanised, and the inguinal lymph nodes (LN), the spleen, the lungs as well as all liver lobes were isolated and immediately assayed for radioactive gamma decoy (cpm). Statistical differences are indicated when * p ! 0.05, as analysed by the Mann-Whitney U test.
higher than the dose needed for subcutaneous immunisation [29] . The results presented in the current study show that direct intralymphatic injection enhances immunogenicity of allergens as compared with the classical subcutaneous SIT route of administration. These results are in line with already published data showing enhanced immunogenicity of intralymphatic injection using plasmid DNA vaccines [17] , major histocompatibility complex class I binding peptides [18] and tumour cells [28] . Other groups have also demonstrated enhanced efficacy by targeted lymph node immunisation with immunostimulatory complexes [30] , bacteriophages [31] , a recombinant simian immunodeficiency virus vaccine [32] , and a canary pox virus-based cancer vaccine [33] . In addition, intralymphatic administration required less than 1% antigen [17] or immune stimulatory molecules [34] to induce potent cytotoxic T-cell immune responses than did subcutaneous antigen administration. In the present study, intralymphatic immunisation was shown to stimulate humoral immune responses comparable with that of subcutaneous SIT, but using only 1% of the allergen dose. Moreover, while subcutaneous SIT induced mostly IgG1 antibodies, intralymphatic allergen administration stimulated both Th1-and Th2-associated antibody subclasses. The enhanced humoral immune responses observed after intralymphatic immunisation were consistent with a general increase in the secretion of cytokines after restimulation of the lymphocytes in vitro.
The reason why the intralymphatic route of immunisation was more efficient than subcutaneous allergen administration in stimulating immune responses, especially of the Th1 type, is most likely a matter of dose and localisation, as proposed by the geographical concept of immune reactivity that emphasises the importance of antigen localisation [15] . As conventional T-and B-cell responses can only be induced in organised lymphoid tissues, the direct injection of antigens into subcutaneous lymph nodes would obviously facilitate the stimulation of stronger immune responses. As demonstrated in the biodistribution experiments using radioactively labelled proteins, only a few percentage of the subcutaneously injected material drained and remained in the lymphatic tissue (spleen and inguinal lymph nodes), while most of the material ended up in the liver. In contrast, after intralymphatic administration, the entire allergen dose is available for antigen presentation in the lymph node. This, and the fact that high antigen doses favour Th1-like immune responses [35, 36] , could explain why efficient lymphatic targeting of the allergen is important for the stimulation of protective immune responses in SIT.
As lower therapeutic doses are required to induce comparably strong immune responses, intralymphatic immunotherapy should improve the safety of immunotherapy and reduce the risk of local and systemic allergic side effects. Although the presence of mast cells as well as basophils has been described in the lymph node [37] , we found excellent local tolerance of allergen injection into inguinal lymph nodes in our clinical trial [38] .
Recently, intralymphatic immunotherapy has been tested in humans for the treatment of both grass pollen and bee venom allergies, demonstrating the clinical feasibility and efficacy of this approach [38] . The injection into subcutaneous lymph nodes has also been applied in the treatment of other diseases, such as cancer [33] .
In conclusion, the intralymphatic route of administration may represent a promising method to increase the efficacy of SIT, to reduce the required allergen dose and number of injections, and to reduce the risk of adverse events as compared with conventional subcutaneous immunotherapy.
